PET and PET/CT in endocrine tumours

Eur J Radiol. 2010 Mar;73(3):481-93. doi: 10.1016/j.ejrad.2009.12.024. Epub 2010 Jan 20.

Abstract

Functional information provided by PET tracers together with the superior image quality and the better data quantification by PET technology had a changing effect on the significance of nuclear medicine in medical issues. Recently introduced hybrid PET/CT systems together with the introduction of novel PET radiopharmaceuticals have contributed to the fact that nuclear medicine has become a growing diagnostic impact on endocrinology. In this review imaging strategies, different radiopharmaceuticals including the basic mechanism of their cell uptake, and the diagnostic value of PET and PET/CT in endocrine tumours except differentiated thyroid carcinomas will be discussed.

Publication types

  • Review

MeSH terms

  • Carbon Radioisotopes
  • Dihydroxyphenylalanine / analogs & derivatives
  • Endocrine Gland Neoplasms / diagnostic imaging*
  • Fluorodeoxyglucose F18
  • Gallium Radioisotopes
  • Humans
  • Image Interpretation, Computer-Assisted / methods
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed / methods*

Substances

  • Carbon Radioisotopes
  • Gallium Radioisotopes
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • fluorodopa F 18
  • Dihydroxyphenylalanine